الصفحة الرئيسية>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Oxyphenisatin acetate

Oxyphenisatin acetate

رقم الكتالوجGC33446

يستخدم أوكسي فينيساتين أسيتات ، وهو عقار أوكسيفينيساتين ، ليكون ملينًا

Products are for research use only. Not for human use. We do not sell to patients.

Oxyphenisatin acetate التركيب الكيميائي

Cas No.: 115-33-3

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
50٫00
متوفر
10mg
46٫00
متوفر
50mg
101٫00
متوفر
100mg
147٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

Oxyphenisatin acetate, the pro-drug of oxyphenisatin, is used to be a laxative.

Oxyphenisatin acetate inhibits the growth of the breast cancer cell lines MCF7, T47D, HS578T, and MDA-MB-468. In the estrogen receptor (ER) positive MCF7 and T47D cells, oxyphenisatin acetate induces TNFα expression and TNFR1 degradation, indicating autocrine receptor-mediated apoptosis in these lines. Ten micromoles per liter Oxyphenisatin acetate treatment results in autophagy and mitochondrial dysfunction[1].

Oxyphenisatin acetate (300 mg/kg, i.p.) delivers intraperitoneally inhibited tumor growth, accompanied by phosphorylation of eIF2α and degradation of TNFR1 in an MCF7 xenograft model[1].

[1]. Morrison BL, et al. Oxyphenisatin acetate (NSC 59687) triggers a cell starvation response leading to autophagy, mitochondrial dysfunction, and autocrine TNFα-mediated apoptosis. Cancer Med. 2013 Oct;2(5):687-700.

مراجعات

Review for Oxyphenisatin acetate

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Oxyphenisatin acetate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.